Sosei announces that its first drug, HTL0014242, has been developed

Recently, Japan's bio
medicine(http://giant Sosei announced that the first subject stake has taken itsdrug(http://HTL0014242, a new type of small molecule compound, thistest(http://will test the drug's ability to slow neurodegenerationthis phase 1 clinical study marks the beginning of a new in-house clinical development programsosei(http:// that focuses on mental and neurological disordersGlutamate is one of the most abundant excitatory neurotransmitters in the human nervous system, and changes in glucosignalation and mGlu5 are associated with a range of neuropsychotic and neurodegenerative diseasesabout HTL0014242HTL0014222 is one of a series of mGlu5 negative deconsocullification regulators designed to selectively and effectively reduce excess glutamate signaling and provide new treatment opportunities for unmetmedical (http:// needs The metabolic glutamate receptor is a Class C GPCR that responds to the neurotransmitter glutamate and receptor subtype 5 (mGlu5), which is of considerable research significance as a drug target an earlier study showed that the new mGlu5 negative variant regulator in mouse MND models slowed the decline in motor function in the late stages of disease progression, which meant that it reduced nerve inflammation and played a protective role in the nerves Compared to the control mice, the reduction in motor neuron loss in the mice after taking the drug proved this   Sosei is the first double-blind, randomized, oral single-dose study in the UK to assess the safety, tolerability and pharmacokinetic results of HTL0014242 in up to 48 subjects, with preliminary results expected in the second half of 2019